Academic Journals Database
Disseminating quality controlled scientific knowledge

Developments and Challenges for mAb-Based Therapeutics

Author(s): Sumit Goswami | Wei Wang | Tsutomu Arakawa | Satoshi Ohtake

Journal: Antibodies
ISSN 2073-4468

Volume: 2;
Issue: 3;
Start page: 452;
Date: 2013;
Original page

Keywords: monoclonal antibody | fusion-proteins | antibody drug conjugates | fragments | bi-specific

The continuous increase in the number of approved monoclonal antibody (mAb)-based therapy suggests that mAbs, and their derivatives, will continue to be the focus of the biotherapeutics industry for years to come. Although vast improvements in our capability to manufacture, characterize, and stabilize mAbs have been achieved, there are still challenges to be overcome. These include analytical and stabilization approaches associated with the development of high concentration mAb formulations. In addition, several mAb-based modalities are under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs), all designed to overcome the limitations encountered with mAb therapy. The current status of their development, with emphasis on manufacturing challenges as well as preliminary clinical results, will be reviewed.
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Jona
Tangokurs Rapperswil-Jona